DarioHealth Far Exceeds 2025 New Client Target with 79 New Accounts Signed Year-to-Date

Rhea-AI Summary

DarioHealth (NASDAQ: DRIO) announced 34 new employer clients in the past two weeks, bringing 79 clients signed year-to-date, surpassing its 2025 target of 40 new clients by 98%. The new agreements cover tens of thousands of lives and are expected to start contributing to revenue in Q1 2026. Nearly all new clients selected Dario for integrated cardiometabolic care. The company cites clinical outcomes including a 1.4% eHbA1c reduction, 38% blood pressure reduction by one stage, and 10% average BMI reduction. A recent JMIR real-world study with Sanofi and Symphony Health reported 23% lower hospitalization rates and 26% lower all-cause charges for Dario users versus matched usual-care individuals.

Positive

• Signed 79 employer clients year-to-date
• 34 new clients added in the past two weeks
• New client revenue expected in Q1 2026
• Clinical outcomes: 1.4% eHbA1c reduction
• JMIR study: 23% lower hospitalization rates

Negative

• Revenue impact delayed until Q1 2026
• Client count exceeds target but unknown contract values
• Tens of thousands covered lives unspecified in exact number

News Market Reaction

+0.76%

1 alert

+0.76% News Effect

On the day this news was published, DRIO gained 0.76%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

New employer clients: 34 clients Total clients YTD: 79 clients 2025 new client target: 40 clients +5 more

8 metrics

New employer clients 34 clients Added in the past two weeks

Total clients YTD 79 clients 2025 year-to-date employer clients signed

2025 new client target 40 clients Original 2025 target for new clients

eHbA1c reduction 1.4% Reduction among Dario platform participants

Blood pressure improvement 38% Reduction by one stage in blood pressure

BMI reduction 10% Average Body Mass Index reduction among participants

Hospitalization rate change 23% lower Dario users vs matched usual-care individuals

All-cause charges change 26% lower Dario users vs matched usual-care individuals

Market Reality Check

Price: $9.95 Vol: Volume 36,333 is 1.22x th...

normal vol

$9.95 Last Close

Volume Volume 36,333 is 1.22x the 20-day average of 29,733, showing modestly elevated activity before this news. normal

Technical Price $12.76 was trading slightly below the 200-day MA at $12.86, with shares still 58.84% under the 52-week high and 115% above the 52-week low.

Peers on Argus

Pre‑news, DRIO’s context showed mixed peers: HCTI -1.6%, MGRX +2.73%, VSEE -1.03...

2 Up

Pre‑news, DRIO’s context showed mixed peers: HCTI -1.6%, MGRX +2.73%, VSEE -1.03%, while momentum names BEAT (+8.97%) and ACON (+8.02%) moved up without news. This points to stock‑specific, not broad sector, drivers.

Historical Context

5 past events · Latest: Dec 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 10	AI product launch	Positive	+4.1%	Launch of DarioIQ conversational AI layer for hypertension members.
Dec 09	Capital raise	Negative	+0.1%	Private placement of 2,713,180 shares for about $17.5M gross proceeds.
Dec 04	Clinical data	Positive	+1.3%	JMIR Cardio study showing sustained blood pressure improvement in users.
Dec 02	Commercial update	Positive	+0.8%	Reported 79 employer clients YTD, nearly doubling 2025 new-client target.
Nov 24	Cost-savings study	Positive	-7.2%	JMIR study estimating $5,077 annual medical cost savings per user.

Pattern Detected

Recent DRIO news has mostly led to price moves consistent with positive fundamentals, though the November JMIR cost-savings study saw a notable negative divergence.

Recent Company History

Over the last few months, DRIO reported several milestones. On Nov 24, 2025, a JMIR study showed 23.5% lower hospitalizations and estimated $5,077 annual savings per user, yet shares fell 7.23%. Subsequent JMIR Cardio data on Dec 4 and the current announcement of 79 employer clients year‑to‑date reinforced clinical and commercial traction, both with positive price reactions. An earlier private placement for about $17.5M had little price impact, while the Dec 10 DarioIQ™ AI launch aligned with a 4.11% gain.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-10-20

An effective S-3 resale registration filed on Oct 20, 2025 covers up to 2,713,180 shares of common stock for selling stockholders. The company receives no proceeds from these sales, but the registered shares can represent an overhang if selling stockholders choose to transact.

Market Pulse Summary

This announcement highlighted that DarioHealth signed 34 new employer clients in two weeks, reaching...

Analysis

This announcement highlighted that DarioHealth signed 34 new employer clients in two weeks, reaching 79 clients year‑to‑date and surpassing its 2025 new‑client target. Reported outcomes include a 1.4% eHbA1c reduction, 38% blood pressure improvement by one stage, and a 10% average BMI reduction, alongside 23% lower hospitalizations and 26% lower all‑cause charges. In context of recent operating losses and debt from SEC filings, investors may track contract ramp timing into H1 2026 and durability of employer adoption.

Key Terms

cardiometabolic, Body Mass Index (BMI), peer-reviewed, return on investment ("ROI"), +1 more

5 terms

cardiometabolic medical

"selected Dario to address a range of cardiometabolic conditions"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

Body Mass Index (BMI) medical

"an average 10% Body Mass Index (BMI) reduction among participants"

Body mass index (BMI) is a simple number calculated from a person’s weight and height that gives a rough indication of whether their body size falls into categories such as underweight, normal, overweight, or obese. For investors, BMI matters because it’s a common screening measure used in public health, insurance underwriting, clinical trials and market research; shifts in population BMI can affect demand for medical services, drugs, insurance costs and related business risks, like a quick fuel-gauge that signals broader health trends.

peer-reviewed technical

"a highly substantial body of peer-reviewed data demonstrating return on investment"

Peer-reviewed means a study, report or paper has been examined and approved by independent experts in the same field before publication, like having multiple qualified inspectors check a building plan. For investors, peer review signals that methods and conclusions have passed scrutiny beyond the author’s claims, making scientific, clinical or technical findings more reliable and reducing the chance that decisions or valuation are based on unchecked or flawed evidence.

return on investment ("ROI") financial

"peer-reviewed data demonstrating return on investment ("ROI") for payers"

A measure of how much money you gain or lose on an investment compared with the amount you put in, usually shown as a percentage. Investors use it to compare how efficiently different opportunities turn dollars into profit—like comparing miles per gallon between cars to see which one gives more value from the same amount of fuel—helping decide which investments deliver the best return for the risk taken.

Journal of Medical Internet Research (JMIR) technical

"study ... was published in the Journal of Medical Internet Research (JMIR)"

An international, peer-reviewed scientific journal that publishes research on digital health, mobile health apps, telemedicine, medical software and how the internet is used in healthcare. Investors care because studies in the journal can act like independent product tests or roadmaps for market adoption: positive findings can boost a digital health company's credibility, user uptake, regulatory standing and potential revenue, while critical findings can signal risks to growth and valuation.

AI-generated analysis. Not financial advice.

34 new employer clients added in the past two weeks expected to contribute to H1 2026 revenue

Data-driven outcomes drive employer adoption, highlighting Dario's market leadership as partner of choice, underscoring employer confidence, repeatability and scalability

NEW YORK, Dec. 2, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) (the "Company", "DarioHealth" or "Dario"), a leader in global digital health, today announced that it has secured 34 new employer clients in the past two weeks, reaching a total of 79 clients signed year-to-date, exceeding its 2025 target of 40 new clients by 98%. These new agreements, which collectively represent tens of thousands of covered lives, further validate Dario's strong penetration, stickiness and repeatability in the mid-size employer market. Revenue from these 34 new client signings is expected to begin in the first quarter of 2026.

Nearly all the newly signed employers selected Dario to address a range of cardiometabolic conditions, underscoring the continued market shift toward integrated digital platforms capable of addressing multiple chronic conditions in one experience that drives measurable outcomes.

"Our latest client wins reflect the power of a single, comprehensive cardiometabolic offering that employers trust to deliver real results," said Steven Nelson, Dario's President and Chief Commercial Officer. "With outcomes such as a 1.4% reduction in eHbA1c, a 38% reduction in blood pressure by one stage and an average 10% Body Mass Index (BMI) reduction among participants, we are showing that our platform doesn't just engage – it delivers. These evidence-based results are resonating strongly with self-insured employers seeking comprehensive, proven solutions for their populations, and the 34 additional signings in the past few weeks alone are a testament to the power and efficacy of our one-to-many channel partner strategy, as well as a strong validation of demand for our products." 

By delivering a unified solution, Dario continues to differentiate our solution in the employer marketplace and build repeatable, scalable growth across self-insured employers seeking measurable clinical and financial outcomes. The Company's ongoing success in expanding its employer client base reflects strong market momentum driven by growing awareness of real-world economic outcomes and continued adoption of its integrated digital health platform among self-insured employers and payers seeking measurable return on investment.

Dario has a highly substantial body of peer-reviewed data demonstrating return on investment ("ROI") for payers that exceeds other digital health companies. The most recent study of Dario's platform, conducted by Sanofi and Symphony Health, was published in the Journal of Medical Internet Research (JMIR), a highly influential digital health journal. Representing a high-rigor, real world analysis, the study found Dario users, as compared to matched individuals receiving usual care, had 23% lower hospitalization rates and 26% lower all-cause charges.

About DarioHealth Corp. (NASDAQ: DRIO)

DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expected timing of its future revenue from its new client agreements, that the new agreements validate its strong penetration, stickiness and repeatability in the mid-size employer market, the benefits of its products, the belief that its products evidence-based results are resonating strongly with self-insured employers, and that the recent agreement signings are a testament to the power and efficacy of its one-to-many channel partner strategy, as well as a strong validation of demand for  products. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contacts

Michael Lipari
SVP Corporate Development
irteam@dariohealth.com
+1-201-785-6310

Rob Halpern
SVP Marketing
irteam@dariohealth.com

https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/dariohealth-far-exceeds-2025-new-client-target-with-79-new-accounts-signed-year-to-date-302630106.html

SOURCE DarioHealth Corp.

FAQ

How many new employer clients did DarioHealth (DRIO) sign in 2025?

DarioHealth signed 79 employer clients year-to-date in 2025.

What is the revenue timing for the 34 new DRIO client signings?

Revenue from the 34 new client signings is expected to begin in Q1 2026.

How much did DarioHealth exceed its 2025 new-client target (DRIO)?

DarioHealth exceeded its 2025 target of 40 new clients by 98%.

What clinical outcomes did DarioHealth cite for its cardiometabolic platform (DRIO)?

Reported outcomes include 1.4% eHbA1c reduction, 38% blood pressure reduction by one stage, and 10% average BMI reduction.

What did the JMIR study with Sanofi and Symphony Health find about DRIO users?

The JMIR study reported DRIO users had 23% lower hospitalization rates and 26% lower all-cause charges versus matched usual-care individuals.